In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

H. Lundbeck gets European rights to Cephalon CNS drug

Executive Summary

Danish developer of central nervous system therapeutics, H. Lundbeck AS, has licensed exclusive European rights to Cephalon's small-molecule, stress-activated protein (SAP) kinase-inhibiting CEP1347, now beginning Phase I trials for neurodegenerative diseases such as Parkinson's and Alzheimer's.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies